search
Back to results

Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract (iNDUCT)

Primary Purpose

Urothelial Carcinoma, Cancer

Status
Recruiting
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Patients receiving neoadjuvant therapy before radical nephrectomy
Sponsored by
Centre Hospitalier Universitaire de Nīmes
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urothelial Carcinoma focused on measuring Durvalumab, Gemcitabine, Cisplatin, Chemotherapy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient has been correctly informed and has given signed consent.
  • Patient is covered by a health insurance scheme.
  • Patients aged over 70 must have a G8 score (Soubeyran et al. 2014) of at least 14.
  • Patient's body weight must be over 30kg
  • Patient has high-grade urothelial carcinoma of the renal pelvis or ureter confirmed histologically (uteroscopic biopsy) or cytologically (urine cytology).
  • Presence of divergent histologies (i.e. squamous cell tumour, adenocarcinoma, small cell carcinoma, micropapillary variant) may also give rise to inclusion if there is a high prevalence (over 90%) of a urothelial component.
  • Presence of EITHER high-grade disease on the uteroscopic tumor biopsy
  • OR Presence of high-grade disease on urine cytology AND infiltrative aspect of renal pelvis/ ureteral wall on the CT scan (presence of hydronephrosis will be considered invasive by definition) with negative cystoscopy.
  • No prior systemic therapies.
  • ECOG performance status 0 to 1.
  • M0 No or N1 disease on CT scan.

    • Required initial laboratory values :
  • Absolute neutrophil count of over 1500 cells/mm²
  • Platelet count of over 100,000 cells/mm3
  • Hemoglobin over 9.0 g/dL
  • Bilirubin below 1.5 times the Upper Limit of Normal for the institution
  • Aspartase transaminase (ASAT) and Alanine transaminase (ALAT) below 2.5 x the Upper Limit of Normal for the institution.
  • Alkaline phosphatase below 2.5 times the Upper Limit of Normal for the institution
  • INR and aPTT below 1.5 times the Upper Limit of Normal for the institution.
  • For Cohort 1 : An estimated glomerular filtration rate of over 60ml/min/1.73m² using the CKD-EPI and/or MDRD equation.
  • For Cohort 2 : An estimated glomerular filtration rate of 40ml to 60ml/min/1.73m² using the CKD-EPI and/or MDRD equation.
  • Patients with reproductive potential must use an effective method to avoid pregnancy for the duration of the trial.
  • Patients must have a life expectancy of at least 12 weeks.

Exclusion Criteria:

  • The patient is participating in another interventional trial;
  • or is in an exclusion period determined by a previous study;
  • or is under judicial protection, or is an adult under guardianship
  • or refuses to sign the consent;
  • or it is impossible to correctly inform the patient.
  • The patient is pregnant or breastfeeding.
  • Concomitant diagnosis of muscle invasive or in situ or high grade non muscle invasive urothelial carcinoma of the bladder.
  • Evidence of NYHA functional class III or IV heart disease.
  • Serious intercurrent medical or psychiatric illness, including serious active infection.
  • Concomitant use of any other investigational drugs.
  • Diagnosis of immunodeficiency or received systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study registration.
  • Additional malignancy within last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer that has undergone potentially curative therapy, stable (as defined by PSA change, checked within 30 days) and untreated very low-risk or low-risk prostate cancer defined by current NCCN guidelines. Previous history of a unique non-muscle invasive bladder cancer is acceptable.
  • Active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. NOTE: Subjects with vitiligo or resolved childhood asthma/atopy would be an exception. Subjects that require systemic corticosteroids at physiologic doses not exceed 10mg/day of prednisone or its equivalent would not be excluded from the study. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study.
  • History of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
  • Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C.
  • Live vaccine received within 30 days prior to the first dose of trial treatment.
  • Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of treatment. Note: Local surgery of isolated lesions for palliative intent is acceptable.
  • History of allogenic organ transplantation.
  • Uncontrolled intercurrent illness, including but not limited to, on-going or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
  • Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.

Sites / Locations

  • Hôpital Bichat-Claude BernardRecruiting
  • Institut Paoli CalmetteRecruiting
  • Hôpital Saint LouisRecruiting
  • Hôpital Pitié SalpétrièreRecruiting
  • Hôpital Européen Georges PompidouRecruiting
  • Centre hospitalier Lyon SudRecruiting
  • Centre Eugène MarquisRecruiting
  • Hôpital FochRecruiting
  • Iuct OncopoleRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Durvalumab+Gemcitabine/Cisplatin or with Gemcitabine/Carboplatin

Arm Description

This is a single arm including 2 different cohorts : Cohort 1 includes patients on 40mg/ML Gemcitabine/50mg Cisplatin used in combination with 50 mg/mL of intravenous Durvalumab (laboratory code MEDI 4736) every 3 weeks for a total of 4 cycles and Cohort 2 includes patients on 40mg/ML Gemcitabine/450mg Carboplatin used in combination with 50 mg/mL of intravenous Durvalumab (laboratory code MEDI 4736) every 3 weeks for a total of 4 cycles..

Outcomes

Primary Outcome Measures

Pathological complete response in Cohort 1
For Cohort 1 (patients on treatment combining Durvalumab and Gemcitabine associated with Cisplatin) the rate of patients with pathological complete response will be calculated and presented with associated 95% confidence interval on the subpopulation of patients with ureteroscopic biopsy at diagnosis.Pathological complete response is defined as no residual signs of viable tumor cells in tissue samples removed during surgery after treatment. To find out if there is a pathologic complete response, a pathologist will perform an evaluation of the tissue samples under a microscope to see if there are still cancer cells left after the treatment.
Pathological complete response in Cohort 2
For Cohort 2 (patients on treatment combining Durvalumab and Gemcitabine associated with Carboplatin) the rate of patients with pathological complete response will be calculated and presented with associated 95% confidence interval on the subpopulation of patients with ureteroscopic biopsy at diagnosis.Pathological complete response is defined as no residual signs of viable tumor cells in tissue samples removed during surgery after treatment. To find out if there is a pathologic complete response, a pathologist will perform an evaluation of the tissue samples under a microscope to see if there are still cancer cells left after the treatment.

Secondary Outcome Measures

Partial pathological response in Cohort 1
Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.
Partial pathological response in Cohort 2
Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.
Partial pathological response in Cohort 1
Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.
Partial pathological response in Cohort 2
Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.
Partial pathological response in Cohort 1
Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.
Partial pathological response in Cohort 2
Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.
Safety and tolerability of treatment - Cohort 1
The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).
Safety and tolerability of treatment - Cohort 2
The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).
Safety and tolerability of treatment - Cohort 1
The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).
Safety and tolerability of treatment - Cohort 2
The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).
Safety and tolerability of treatment - Cohort 1
The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).
Safety and tolerability of treatment - Cohort 2
The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).
Treatment success - Overall Survival in Cohort 1
The overall Survival rate of Cohort 1 patients will be collected.
Treatment success - bladder recurrence and dissemination in Cohort 1
Bladder recurrence and dissemination in Cohort 1 patients will be collected.
Treatment success - Overall Survival in Cohort 2
The overall Survival rate of Cohort 2 patients will be collected.
Treatment success - bladder recurrence and dissemination in Cohort 2
Bladder recurrence and dissemination will be collected.
Intercycle report : Blood cells & Platelets in Cohort 1
The numbers of each type of blood cell and platelets will be measured per McL
Intercycle report : Blood cells & Platelets in Cohort 2
The numbers of each type of blood cell and platelets will be measured per McL
Intercycle report : Electrolytes in Cohort 1
A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.
Intercycle report : Electrolytes in Cohort 2
A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.
Intercycle report : Liver in Cohort 1 - AST
- Hepatic workup: Aspartate Aminotransferase (AST) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 1 - ALT
- Hepatic workup: Alanine Aminotransferase (ALT) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 1 -GGT
- Hepatic workup: Gamma-Glutamyl Transferase (GGT) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 1 - LDH
- Hepatic workup: Lactate Dehydrogenase (LDH) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 1 - ALP
- Hepatic workup: Alkaline Phosphatase (ALP) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 1 - bilirubin
- Hepatic workup: Bilirubin (free/conjugated) concentration will be measured il micromoles/L
Intercycle report : Liver in Cohort 2 - AST
- Hepatic workup: Aspartate Aminotransferase (AST) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 2 - ALT
- Hepatic workup: Alanine Aminotransferase (ALT) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 2 - GGT
- Hepatic workup: Gamma-Glutamyl Transferase (GGT) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 2 - LDH
- Hepatic workup: Lactate Dehydrogenase (LDH) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 2 - ALP
- Hepatic workup: Alkaline Phosphatase (ALP) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 2 - bilirubin
- Hepatic workup: bilirubin (free/conjugated) concentration will be measured in micromoles/L.
Intercycle report : Creatinine Phosphokinase in Cohort 1
Creatine Phosphokinase will be measured in IU/L. usually between 60 and 400 IU/L
Intercycle report : Creatinine Phosphokinase in Cohort 2
Creatine Phosphokinase will be measured in IU/L. usually between 60 and 400 IU/L
Intercycle report : Thyroid in Cohort 1
A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood.
Intercycle report : Thyroid in Cohort 2
A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood.
Intercycle report : Cortisol in Cohort 1
Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are : 5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.
Intercycle report : Cortisol in Cohort 2
Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are : 5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.
Intercycle report : C-reactive protein in Cohort 1
C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).
Intercycle report : C-reactive protein in Cohort 2
C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).
Intercycle report : Urine in Cohort 1
Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows: (Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)
Intercycle report : Urine in Cohort 2
Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows: (Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)
Intercycle report: N-BNP, troponin in Cohort 1
Serum N-BNP and troponin concentrations will be measured. These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.
Intercycle report: N-BNP, troponin in Cohort 2
Serum N-BNP and troponin concentrations will be measured.These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.
Intercycle report: Blood cells & platelets in Cohort 1
The numbers of each type of blood cell and platelets will be measured per McL
Intercycle report: Blood cells & Platelets in Cohort 2
The numbers of each type of blood cell and platelets will be measured per McL
Intercycle report: Electrolytes in Cohort 1
A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.
Intercycle report : Electrolytes in Cohort 2
A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.
Intercycle report : Liver in Cohort 1 - AST
Hepatic workup: Aspartate Aminotransferase (AST) concentration will be measured in IU/L..
Intercycle report : Liver in Cohort 1 - ALT
Hepatic workup: Aminotransferase (ALT) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 1 - GGT
Hepatic workup: Gamma-Glutamyl Transferase (GGT) concentrations will be measured in IU/L.
Intercycle report : Liver in Cohort 1 - LDH
Hepatic workup: Lactate Dehydrogenase (LDH) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 1 - ALP
Hepatic workup: Alkaline Phosphatase (ALP) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 1 - bilirubin
Hepatic workup: Bilirubin (free/conjugated) concentration will be measured in micromoles/L
Intercycle report : Liver in Cohort 2 - AST
- Hepatic workup: Aspartate Aminotransferase (AST) concentration will be measured.
Intercycle report : Liver in Cohort 2 - ALT
- Hepatic workup: Alanine Aminotransferase (ALT) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 2 - GGT
- Hepatic workup: Gamma-Glutamyl Transferase (GGT) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 2 - LDH
- Hepatic workup: Lactate Dehydrogenase (LDH) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 2 - ALP
- Hepatic workup: Alkaline Phosphatase (ALP) concentration will be measured in IU/L.
Intercycle report : Liver in Cohort 2 - bilirubin
- Hepatic workup: Bilirubin (free/conjugated) concentration will be measured in micromoles/L.
Intercycle report : Creatine Phosphokinase in Cohort 1
- Creatine Phosphokinase will be measured in IU/L. Normal values are usually between 60 and 400 IU/L
Intercycle report : Creatine Phosphokinase in Cohort 2
- Creatine Phosphokinase will be measured in IU/L. usually between 60 and 400 IU/L
Intercycle report : Thyroid in Cohort 1
A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood.
Intercycle report : Thyroid in Cohort 2
A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood.
Intercycle report : Cortisol in Cohort 1
Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are : 5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.
Intercycle report : Cortisol in Cohort 2
Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are : 5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.
Intercycle report : C-reactive protein in Cohort 1
C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).
Intercycle report : C-reactive protein in Cohort 2
C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).
Intercycle report : Urine in Cohort 1
Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows: (Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)
Intercycle report : Urine in Cohort 2
- Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows: (Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)
Intercycle report : N-BNP, troponin in Cohort 1
Serum N-BNP and troponin concentrations will be measured.These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.
Intercycle report : N-BNP, troponin in Cohort 2
Serum N-BNP and troponin concentrations will be measured.These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.
Intercycle report: Blood cells & Platelets in Cohort 1
The numbers of each type of blood cell and platelets will be measured per McL
Intercycle report: Blood cells & Platelets in Cohort 2
The numbers of each type of blood cell and platelets will be measured per McL
Intercycle report: Electrolytes in Cohort 1
A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.
Intercycle report: Electrolytes in Cohort 2
A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.
Intercycle report: Liver in Cohort 1
- Hepatic workup: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Alkaline Phosphatase (ALP) and bilirubin (free/conjugated) concentrations will all be measured.
Intercycle report: Liver in Cohort 2
- Hepatic workup: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Alkaline Phosphatase (ALP) and bilirubin (free/conjugated) concentrations will all be measured.
Intercycle report: Creatine Phosphokinase in Cohort 1
Creatine Phosphokinase Creatine Phosphokinase will be measured in IU/L. usually between 60 and 400 IU/L
Intercycle report: Creatine Phosphokinase in Cohort 2
Creatine Phosphokinase will be measured in IU/L. usually between 60 and 400 IU/L
Intercycle report: Thyroid in Cohort 1
A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood.
Intercycle report: Thyroid in Cohort 2
A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood.
Intercycle report: Cortisol in Cohort 1
Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are : 5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.
Intercycle report: Cortisol in Cohort 2
Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are : 5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.
Intercycle report: C-reactive protein in Cohort 1
C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).
Intercycle report: C-reactive protein in Cohort 2
C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).
Intercycle report : Urine in Cohort 1
Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows: (Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)
Intercycle report: Urine in Cohort 2
Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows: (Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)
Intercycle report: N-BNP, troponin in Cohort 1
Serum N-BNP and troponin concentrations will be measured. These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.
Intercycle report: N-BNP, troponin in Cohort 2
Serum N-BNP and troponin concentrations will be measured. These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.

Full Information

First Posted
October 28, 2020
Last Updated
May 26, 2023
Sponsor
Centre Hospitalier Universitaire de Nīmes
Collaborators
Pitié-Salpêtrière Hospital, Hôpital Bichat-Claude Bernard, 75018 Paris, Hopital Foch 92151 Suresnes, Institut Paoli-Calmettes, European Georges Pompidou Hospital, Saint-Louis Hospital, Paris, France, Centre Hospitalier Lyon Sud, Center Eugene Marquis, IUCT ONCOPOLE
search

1. Study Identification

Unique Protocol Identification Number
NCT04617756
Brief Title
Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract
Acronym
iNDUCT
Official Title
Safety & Efficacy of Neoadjuvant Immunotherapy With Durvalumab (MEDI 4736) Combined With Neoadjuvant Chemotherapy (Gemcitabine/Cisplatin or Gemcitabine/Carboplatin) in Patients With Operable, High-risk, Localized Urothelial Carcinoma of the Upper Urinary Tract
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 29, 2021 (Actual)
Primary Completion Date
January 1, 2025 (Anticipated)
Study Completion Date
October 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Nīmes
Collaborators
Pitié-Salpêtrière Hospital, Hôpital Bichat-Claude Bernard, 75018 Paris, Hopital Foch 92151 Suresnes, Institut Paoli-Calmettes, European Georges Pompidou Hospital, Saint-Louis Hospital, Paris, France, Centre Hospitalier Lyon Sud, Center Eugene Marquis, IUCT ONCOPOLE

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Following radical nephrectomy (RNU) for upper tract urothelial carcinoma (UTUC) most patients face a poor prognosis. Indeed, patients who have undergone RNU for UTUC have 5-year recurrence-free and cancer specific survival probabilities of 69% and 73% respectively. The primary objective of this study is to assess the pathological complete response rate to combination therapy with neoadjuvant durvalumab and chemotherapy (Gemcitabine/Cisplatin) before surgery in patients with high-risk, localized, non-metastatic urothelial carcinomas of the upper tract.
Detailed Description
Following radical nephrectomy (RNU) for upper tract urothelial carcinoma (UTUC) most patients face a poor prognosis. Indeed, patients who have undergone RNU for UTUC have 5-year recurrence-free and cancer specific survival probabilities of 69% and 73% respectively. Additional systemic therapy therefore seems justified for prolonged cancer control. However, there have been very few studies on neoadjuvant/adjuvant therapies in UTUC. Recently, the UK's multicentric POUT trial reported the benefits of adjuvant chemotherapy in UTUC patients. Level 1 evidence has been provided for neoadjuvant therapy for urothelial carcinoma of the bladder via meta-analysis in 2005 but there are also several arguments for systemic therapy in this context especially as most patients lose the function of one kidney and cannot receive nephrotoxic cisplatin-based chemotherapy. Urothelial carcinoma of the upper tract have a different genetic background from carcinomas of the lower tract. The investigators hypothesized that there would be a greater occurrence of lower pathological stages among study group patients who receive neoadjuvant combined Durvalumab/Gemcitabine/Cisplatin or Carboplatin prior to RNU compared to the current literature (Gregg et al. 2018, Almassi et al. 2018). The primary objective is to assess the pathological complete response rate (ypT0) in each cohort and independently of a combination therapy with neoadjuvant durvalumab and chemotherapy (Gemcitabine/Cisplatin) before surgery in patients with high-risk, localized, non-metastatic urothelial carcinomas of the upper tract.Secondary objectives include: assessing partial response rate to treatment, assessing the safety and tolerability of the treatment and evaluating the overall survival, bladder recurrence and dissemination at two years of follow-up.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urothelial Carcinoma, Cancer
Keywords
Durvalumab, Gemcitabine, Cisplatin, Chemotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Model Description
Patients with an estimated glomerular filtration rate equal to or over 60 ml/min./1.73² (cohort 1) will receive treatment combining Durvalumab and gemcitabine with Cisplatin. Patients with an estimated glomerular filtration rate of under 60 ml/min./1.73² and over 40 ml/min./1.73² (cohort 2) will receive treatment combining Durvalumab and gemcitabine with Carboplatin.
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Durvalumab+Gemcitabine/Cisplatin or with Gemcitabine/Carboplatin
Arm Type
Experimental
Arm Description
This is a single arm including 2 different cohorts : Cohort 1 includes patients on 40mg/ML Gemcitabine/50mg Cisplatin used in combination with 50 mg/mL of intravenous Durvalumab (laboratory code MEDI 4736) every 3 weeks for a total of 4 cycles and Cohort 2 includes patients on 40mg/ML Gemcitabine/450mg Carboplatin used in combination with 50 mg/mL of intravenous Durvalumab (laboratory code MEDI 4736) every 3 weeks for a total of 4 cycles..
Intervention Type
Drug
Intervention Name(s)
Patients receiving neoadjuvant therapy before radical nephrectomy
Intervention Description
Chemotherapy using either a combination of Gemcitabine/Cisplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736) or Chemotherapy with either Gemcitibine/Carboplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736)
Primary Outcome Measure Information:
Title
Pathological complete response in Cohort 1
Description
For Cohort 1 (patients on treatment combining Durvalumab and Gemcitabine associated with Cisplatin) the rate of patients with pathological complete response will be calculated and presented with associated 95% confidence interval on the subpopulation of patients with ureteroscopic biopsy at diagnosis.Pathological complete response is defined as no residual signs of viable tumor cells in tissue samples removed during surgery after treatment. To find out if there is a pathologic complete response, a pathologist will perform an evaluation of the tissue samples under a microscope to see if there are still cancer cells left after the treatment.
Time Frame
Week 14 - 18
Title
Pathological complete response in Cohort 2
Description
For Cohort 2 (patients on treatment combining Durvalumab and Gemcitabine associated with Carboplatin) the rate of patients with pathological complete response will be calculated and presented with associated 95% confidence interval on the subpopulation of patients with ureteroscopic biopsy at diagnosis.Pathological complete response is defined as no residual signs of viable tumor cells in tissue samples removed during surgery after treatment. To find out if there is a pathologic complete response, a pathologist will perform an evaluation of the tissue samples under a microscope to see if there are still cancer cells left after the treatment.
Time Frame
Week 14 - 18
Secondary Outcome Measure Information:
Title
Partial pathological response in Cohort 1
Description
Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.
Time Frame
Week 3
Title
Partial pathological response in Cohort 2
Description
Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.
Time Frame
Week 3
Title
Partial pathological response in Cohort 1
Description
Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.
Time Frame
Week 6
Title
Partial pathological response in Cohort 2
Description
Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.
Time Frame
Week 6
Title
Partial pathological response in Cohort 1
Description
Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.
Time Frame
Week 9
Title
Partial pathological response in Cohort 2
Description
Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.
Time Frame
Week 9
Title
Safety and tolerability of treatment - Cohort 1
Description
The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).
Time Frame
Week 3
Title
Safety and tolerability of treatment - Cohort 2
Description
The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).
Time Frame
Week 3
Title
Safety and tolerability of treatment - Cohort 1
Description
The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).
Time Frame
Week 6
Title
Safety and tolerability of treatment - Cohort 2
Description
The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).
Time Frame
Week 6
Title
Safety and tolerability of treatment - Cohort 1
Description
The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).
Time Frame
Week 9
Title
Safety and tolerability of treatment - Cohort 2
Description
The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).
Time Frame
Week 9
Title
Treatment success - Overall Survival in Cohort 1
Description
The overall Survival rate of Cohort 1 patients will be collected.
Time Frame
2 years after surgery.
Title
Treatment success - bladder recurrence and dissemination in Cohort 1
Description
Bladder recurrence and dissemination in Cohort 1 patients will be collected.
Time Frame
2 years after surgery.
Title
Treatment success - Overall Survival in Cohort 2
Description
The overall Survival rate of Cohort 2 patients will be collected.
Time Frame
2 years after surgery.
Title
Treatment success - bladder recurrence and dissemination in Cohort 2
Description
Bladder recurrence and dissemination will be collected.
Time Frame
2 years after surgery.
Title
Intercycle report : Blood cells & Platelets in Cohort 1
Description
The numbers of each type of blood cell and platelets will be measured per McL
Time Frame
Week 3
Title
Intercycle report : Blood cells & Platelets in Cohort 2
Description
The numbers of each type of blood cell and platelets will be measured per McL
Time Frame
Week 3
Title
Intercycle report : Electrolytes in Cohort 1
Description
A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.
Time Frame
Week 3
Title
Intercycle report : Electrolytes in Cohort 2
Description
A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.
Time Frame
Week 3
Title
Intercycle report : Liver in Cohort 1 - AST
Description
- Hepatic workup: Aspartate Aminotransferase (AST) concentration will be measured in IU/L.
Time Frame
Week 3
Title
Intercycle report : Liver in Cohort 1 - ALT
Description
- Hepatic workup: Alanine Aminotransferase (ALT) concentration will be measured in IU/L.
Time Frame
Week 3
Title
Intercycle report : Liver in Cohort 1 -GGT
Description
- Hepatic workup: Gamma-Glutamyl Transferase (GGT) concentration will be measured in IU/L.
Time Frame
Week 3
Title
Intercycle report : Liver in Cohort 1 - LDH
Description
- Hepatic workup: Lactate Dehydrogenase (LDH) concentration will be measured in IU/L.
Time Frame
Week 3
Title
Intercycle report : Liver in Cohort 1 - ALP
Description
- Hepatic workup: Alkaline Phosphatase (ALP) concentration will be measured in IU/L.
Time Frame
Week 3
Title
Intercycle report : Liver in Cohort 1 - bilirubin
Description
- Hepatic workup: Bilirubin (free/conjugated) concentration will be measured il micromoles/L
Time Frame
Week 3
Title
Intercycle report : Liver in Cohort 2 - AST
Description
- Hepatic workup: Aspartate Aminotransferase (AST) concentration will be measured in IU/L.
Time Frame
Week 3
Title
Intercycle report : Liver in Cohort 2 - ALT
Description
- Hepatic workup: Alanine Aminotransferase (ALT) concentration will be measured in IU/L.
Time Frame
Week 3
Title
Intercycle report : Liver in Cohort 2 - GGT
Description
- Hepatic workup: Gamma-Glutamyl Transferase (GGT) concentration will be measured in IU/L.
Time Frame
Week 3
Title
Intercycle report : Liver in Cohort 2 - LDH
Description
- Hepatic workup: Lactate Dehydrogenase (LDH) concentration will be measured in IU/L.
Time Frame
Week 3
Title
Intercycle report : Liver in Cohort 2 - ALP
Description
- Hepatic workup: Alkaline Phosphatase (ALP) concentration will be measured in IU/L.
Time Frame
Week 3
Title
Intercycle report : Liver in Cohort 2 - bilirubin
Description
- Hepatic workup: bilirubin (free/conjugated) concentration will be measured in micromoles/L.
Time Frame
Week 3
Title
Intercycle report : Creatinine Phosphokinase in Cohort 1
Description
Creatine Phosphokinase will be measured in IU/L. usually between 60 and 400 IU/L
Time Frame
Week 3
Title
Intercycle report : Creatinine Phosphokinase in Cohort 2
Description
Creatine Phosphokinase will be measured in IU/L. usually between 60 and 400 IU/L
Time Frame
Week 3
Title
Intercycle report : Thyroid in Cohort 1
Description
A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood.
Time Frame
Week 3
Title
Intercycle report : Thyroid in Cohort 2
Description
A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood.
Time Frame
Week 3
Title
Intercycle report : Cortisol in Cohort 1
Description
Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are : 5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.
Time Frame
Week 3
Title
Intercycle report : Cortisol in Cohort 2
Description
Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are : 5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.
Time Frame
Week 3
Title
Intercycle report : C-reactive protein in Cohort 1
Description
C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).
Time Frame
Week 3
Title
Intercycle report : C-reactive protein in Cohort 2
Description
C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).
Time Frame
Week 3
Title
Intercycle report : Urine in Cohort 1
Description
Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows: (Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)
Time Frame
Week 3
Title
Intercycle report : Urine in Cohort 2
Description
Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows: (Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)
Time Frame
Week 3
Title
Intercycle report: N-BNP, troponin in Cohort 1
Description
Serum N-BNP and troponin concentrations will be measured. These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.
Time Frame
Week 3
Title
Intercycle report: N-BNP, troponin in Cohort 2
Description
Serum N-BNP and troponin concentrations will be measured.These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.
Time Frame
Week 3
Title
Intercycle report: Blood cells & platelets in Cohort 1
Description
The numbers of each type of blood cell and platelets will be measured per McL
Time Frame
Week 6
Title
Intercycle report: Blood cells & Platelets in Cohort 2
Description
The numbers of each type of blood cell and platelets will be measured per McL
Time Frame
Week 6
Title
Intercycle report: Electrolytes in Cohort 1
Description
A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.
Time Frame
Week 6
Title
Intercycle report : Electrolytes in Cohort 2
Description
A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.
Time Frame
Week 6
Title
Intercycle report : Liver in Cohort 1 - AST
Description
Hepatic workup: Aspartate Aminotransferase (AST) concentration will be measured in IU/L..
Time Frame
Week 6
Title
Intercycle report : Liver in Cohort 1 - ALT
Description
Hepatic workup: Aminotransferase (ALT) concentration will be measured in IU/L.
Time Frame
Week 6
Title
Intercycle report : Liver in Cohort 1 - GGT
Description
Hepatic workup: Gamma-Glutamyl Transferase (GGT) concentrations will be measured in IU/L.
Time Frame
Week 6
Title
Intercycle report : Liver in Cohort 1 - LDH
Description
Hepatic workup: Lactate Dehydrogenase (LDH) concentration will be measured in IU/L.
Time Frame
Week 6
Title
Intercycle report : Liver in Cohort 1 - ALP
Description
Hepatic workup: Alkaline Phosphatase (ALP) concentration will be measured in IU/L.
Time Frame
Week 6
Title
Intercycle report : Liver in Cohort 1 - bilirubin
Description
Hepatic workup: Bilirubin (free/conjugated) concentration will be measured in micromoles/L
Time Frame
Week 6
Title
Intercycle report : Liver in Cohort 2 - AST
Description
- Hepatic workup: Aspartate Aminotransferase (AST) concentration will be measured.
Time Frame
Week 6
Title
Intercycle report : Liver in Cohort 2 - ALT
Description
- Hepatic workup: Alanine Aminotransferase (ALT) concentration will be measured in IU/L.
Time Frame
Week 6
Title
Intercycle report : Liver in Cohort 2 - GGT
Description
- Hepatic workup: Gamma-Glutamyl Transferase (GGT) concentration will be measured in IU/L.
Time Frame
Week 6
Title
Intercycle report : Liver in Cohort 2 - LDH
Description
- Hepatic workup: Lactate Dehydrogenase (LDH) concentration will be measured in IU/L.
Time Frame
Week 6
Title
Intercycle report : Liver in Cohort 2 - ALP
Description
- Hepatic workup: Alkaline Phosphatase (ALP) concentration will be measured in IU/L.
Time Frame
Week 6
Title
Intercycle report : Liver in Cohort 2 - bilirubin
Description
- Hepatic workup: Bilirubin (free/conjugated) concentration will be measured in micromoles/L.
Time Frame
Week 6
Title
Intercycle report : Creatine Phosphokinase in Cohort 1
Description
- Creatine Phosphokinase will be measured in IU/L. Normal values are usually between 60 and 400 IU/L
Time Frame
Week 6
Title
Intercycle report : Creatine Phosphokinase in Cohort 2
Description
- Creatine Phosphokinase will be measured in IU/L. usually between 60 and 400 IU/L
Time Frame
Week 6
Title
Intercycle report : Thyroid in Cohort 1
Description
A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood.
Time Frame
Week 6
Title
Intercycle report : Thyroid in Cohort 2
Description
A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood.
Time Frame
Week 6
Title
Intercycle report : Cortisol in Cohort 1
Description
Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are : 5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.
Time Frame
Week 6
Title
Intercycle report : Cortisol in Cohort 2
Description
Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are : 5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.
Time Frame
Week 6
Title
Intercycle report : C-reactive protein in Cohort 1
Description
C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).
Time Frame
Week 6
Title
Intercycle report : C-reactive protein in Cohort 2
Description
C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).
Time Frame
Week 6
Title
Intercycle report : Urine in Cohort 1
Description
Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows: (Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)
Time Frame
Week 6
Title
Intercycle report : Urine in Cohort 2
Description
- Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows: (Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)
Time Frame
Week 6
Title
Intercycle report : N-BNP, troponin in Cohort 1
Description
Serum N-BNP and troponin concentrations will be measured.These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.
Time Frame
Week 6
Title
Intercycle report : N-BNP, troponin in Cohort 2
Description
Serum N-BNP and troponin concentrations will be measured.These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.
Time Frame
Week 6
Title
Intercycle report: Blood cells & Platelets in Cohort 1
Description
The numbers of each type of blood cell and platelets will be measured per McL
Time Frame
Week 9
Title
Intercycle report: Blood cells & Platelets in Cohort 2
Description
The numbers of each type of blood cell and platelets will be measured per McL
Time Frame
Week 9
Title
Intercycle report: Electrolytes in Cohort 1
Description
A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.
Time Frame
Week 9
Title
Intercycle report: Electrolytes in Cohort 2
Description
A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.
Time Frame
Week 9
Title
Intercycle report: Liver in Cohort 1
Description
- Hepatic workup: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Alkaline Phosphatase (ALP) and bilirubin (free/conjugated) concentrations will all be measured.
Time Frame
Week 9
Title
Intercycle report: Liver in Cohort 2
Description
- Hepatic workup: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Alkaline Phosphatase (ALP) and bilirubin (free/conjugated) concentrations will all be measured.
Time Frame
Week 9
Title
Intercycle report: Creatine Phosphokinase in Cohort 1
Description
Creatine Phosphokinase Creatine Phosphokinase will be measured in IU/L. usually between 60 and 400 IU/L
Time Frame
Week 9
Title
Intercycle report: Creatine Phosphokinase in Cohort 2
Description
Creatine Phosphokinase will be measured in IU/L. usually between 60 and 400 IU/L
Time Frame
Week 9
Title
Intercycle report: Thyroid in Cohort 1
Description
A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood.
Time Frame
Week 9
Title
Intercycle report: Thyroid in Cohort 2
Description
A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood.
Time Frame
Week 9
Title
Intercycle report: Cortisol in Cohort 1
Description
Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are : 5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.
Time Frame
Week 9
Title
Intercycle report: Cortisol in Cohort 2
Description
Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are : 5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.
Time Frame
Week 9
Title
Intercycle report: C-reactive protein in Cohort 1
Description
C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).
Time Frame
Week 9
Title
Intercycle report: C-reactive protein in Cohort 2
Description
C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).
Time Frame
Week 9
Title
Intercycle report : Urine in Cohort 1
Description
Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows: (Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)
Time Frame
Week 9
Title
Intercycle report: Urine in Cohort 2
Description
Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows: (Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)
Time Frame
Week 9
Title
Intercycle report: N-BNP, troponin in Cohort 1
Description
Serum N-BNP and troponin concentrations will be measured. These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.
Time Frame
Week 9
Title
Intercycle report: N-BNP, troponin in Cohort 2
Description
Serum N-BNP and troponin concentrations will be measured. These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.
Time Frame
Week 9
Other Pre-specified Outcome Measures:
Title
Tumor staging in Cohort 1
Description
Via computed tomographic urography, tumor classification will be performed using the 2017 TNM classification for upper urothelial tract carcinomas. High-risk UTUC is defined by risk stratification following EAU guidelines. Endoluminal filling defects surrounded by opacified urine will be considered as non-infiltrative lesions corresponding to Stage T1. Focal thickening of the urethral wall or renal pelvis = Stage T2. Fat infiltration in front of the parietal thickening or infiltration of kidney tissue = Stage T3.
Time Frame
Just before surgery at weeks 14 to 18
Title
Tumor staging in Cohort 2
Description
Via computed tomographic urography, tumor classification will be performed using the 2017 TNM classification for upper urothelial tract carcinomas. High-risk UTUC is defined by risk stratification following EAU guidelines. Endoluminal filling defects surrounded by opacified urine will be considered as non-infiltrative lesions corresponding to Stage T1. Focal thickening of the urethral wall or renal pelvis = Stage T2. Fat infiltration in front of the parietal thickening or infiltration of kidney tissue = Stage T3.
Time Frame
Just before surgery at weeks 14 to 18
Title
Results of biopsy on tissue specimens after surgery in Cohort 1
Description
After surgery, paraffin-embedded tissues and tissues frozen to -80° obtained during surgery will be evaluated by Ventana 623 assay. The PD-L1 status of both tumor cells and immune cells will be recorded.
Time Frame
After surgery at weeks 14 to 18
Title
Results of biopsy on tissue specimens after surgery in Cohort 2
Description
After surgery, paraffin-embedded tissues and tissues frozen to -80° obtained during surgery will be evaluated by Ventana 623 assay. The PD-L1 status of both tumor cells and immune cells will be recorded.
Time Frame
After surgery at weeks 14 to 18
Title
Overall survival in Cohort 1
Description
The overall survival rate of patients in Cohort 1 will be noted following a phone-call to the patient's home. If the patient has died, information regarding the cause of death will be sought from the INSERM's Cepi-DC file (where all records of deceased patients are kept).
Time Frame
Approximately two years after surgery
Title
Overall survival in Cohort 2
Description
The overall survival rate of patients in Cohort 2 will be noted following a phone-call to the patient's home.If the patient has died, information regarding the cause of death will be sought from the INSERM's Cepi-DC file (where all records of deceased patients are kept).
Time Frame
Approximately two years after surgery
Title
Bladder recurrence in Cohort 1
Description
A phone-call to the patient's home will be made and any bladder recurrence will be noted.
Time Frame
Approximately two years after surgery
Title
Bladder recurrence in Cohort 2
Description
A phone-call to the patient's home will be made and any bladder recurrence will be noted.
Time Frame
Approximately two years after surgery
Title
Dissemination in Cohort 1
Description
A phone-call to the patient's home will be made and any tumor dissemination will be noted.
Time Frame
Approximately two years after surgery
Title
Dissemination in Cohort 2
Description
A phone-call to the patient's home will be made and any tumor dissemination will be noted.
Time Frame
Approximately two years after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient has been correctly informed and has given signed consent. Patient is covered by a health insurance scheme. Patients aged over 70 must have a G8 score (Soubeyran et al. 2014) of at least 14. Patient's body weight must be over 30kg Patient has high-grade urothelial carcinoma of the renal pelvis or ureter confirmed histologically (uteroscopic biopsy) or cytologically (urine cytology). Presence of divergent histologies (i.e. squamous cell tumour, adenocarcinoma, small cell carcinoma, micropapillary variant) may also give rise to inclusion if there is a high prevalence (over 90%) of a urothelial component. Presence of EITHER high-grade disease on the uteroscopic tumor biopsy OR Presence of high-grade disease on urine cytology AND infiltrative aspect of renal pelvis/ ureteral wall on the CT scan (presence of hydronephrosis will be considered invasive by definition) with negative cystoscopy. Or in the absence of histological evidence, the opinion of the multidisciplinary consultation meeting (RCP) will prevail for the analysis of the imaging and the potential inclusion of the patient in the study No prior systemic therapies. ECOG performance status 0 to 1. M0 No or N1 disease on CT scan. Required initial laboratory values : Absolute neutrophil count of over 1500 cells/mm² Platelet count of over 100,000 cells/mm3 Hemoglobin over 9.0 g/dL Bilirubin below 1.5 times the Upper Limit of Normal for the institution Aspartase transaminase (ASAT) and Alanine transaminase (ALAT) below 2.5 x the Upper Limit of Normal for the institution. Alkaline phosphatase below 2.5 times the Upper Limit of Normal for the institution INR and aPTT below 1.5 times the Upper Limit of Normal for the institution. For Cohort 1 : An estimated glomerular filtration rate of over 60ml/min/1.73m² using the CKD-EPI and/or MDRD equation. For Cohort 2 : An estimated glomerular filtration rate of 40ml to 60ml/min/1.73m² using the CKD-EPI and/or MDRD equation. Patients with reproductive potential must use an effective method to avoid pregnancy for the duration of the trial. Patients must have a life expectancy of at least 12 weeks. Exclusion Criteria: The patient is participating in another interventional trial; or is in an exclusion period determined by a previous study; or is under judicial protection, or is an adult under guardianship or refuses to sign the consent; or it is impossible to correctly inform the patient. The patient is pregnant or breastfeeding. Concomitant diagnosis of muscle invasive or in situ or high grade non muscle invasive urothelial carcinoma of the bladder. Evidence of NYHA functional class III or IV heart disease. Serious intercurrent medical or psychiatric illness, including serious active infection. Concomitant use of any other investigational drugs. Diagnosis of immunodeficiency or received systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study registration. Additional malignancy within last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer that has undergone potentially curative therapy, stable (as defined by PSA change, checked within 30 days) and untreated very low-risk or low-risk prostate cancer defined by current NCCN guidelines. Previous or concomitant history of non-muscle invasive bladder cancer is acceptable. Active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. NOTE: Subjects with vitiligo or resolved childhood asthma/atopy would be an exception. Subjects that require systemic corticosteroids at physiologic doses not exceed 10mg/day of prednisone or its equivalent would not be excluded from the study. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study. History of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C. Live vaccine received within 30 days prior to the first dose of trial treatment. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of treatment. Note: Local surgery of isolated lesions for palliative intent is acceptable. History of allogenic organ transplantation. Uncontrolled intercurrent illness, including but not limited to, on-going or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nadine HOUEDE, Pr.
Phone
+33 4 66 68 33 01
Email
nadine.HOUEDE@chu-nimes.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Annissa MEZGARI
Phone
+33 4 66 68 30 52
Email
drc@chu-nimes.fr
Facility Information:
Facility Name
Hôpital Bichat-Claude Bernard
City
Paris
State/Province
Paris Cx 20
ZIP/Postal Code
75018
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Evanguelos XYLINAS
Email
evanguelosxylinas@aphp.fr
Facility Name
Institut Paoli Calmette
City
Marseille
ZIP/Postal Code
13009
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gwénaëlle Gravis
Email
gravisg@ipc.unicancer.fr
Facility Name
Hôpital Saint Louis
City
Paris
ZIP/Postal Code
75010
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexandra Masson-Lecomte
Email
alexandra.massonlecomte@aphp.fr
Facility Name
Hôpital Pitié Salpétrière
City
Paris
ZIP/Postal Code
75013 Paris
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Morgan ROUPRET, PUPH
Phone
01 42 17 72 97
Email
mroupret@gmail.com
Facility Name
Hôpital Européen Georges Pompidou
City
Paris
ZIP/Postal Code
75015
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
François Audenet
Email
francois.audenet@gmail.com
Facility Name
Centre hospitalier Lyon Sud
City
Pierre Bénite
ZIP/Postal Code
69310
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sophie TARTAS
Email
Sophie.tartas@chu-lyon.fr
Facility Name
Centre Eugène Marquis
City
Rennes
ZIP/Postal Code
35042
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brigitte LAGUERRE
Phone
0299253182
Email
b.laguerre@rennes.unicancer.fr
Facility Name
Hôpital Foch
City
Suresnes
ZIP/Postal Code
92151
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yann Neuzillet
Email
y.neuzillet@hopital-foch.org
Facility Name
Iuct Oncopole
City
Toulouse Cedex 9
ZIP/Postal Code
31059
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Damien POUESSEL
Email
pouessel.damien@iuct-oncopole.fr

12. IPD Sharing Statement

Learn more about this trial

Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract

We'll reach out to this number within 24 hrs